Cutaneous adverse events due to immune checkpoint inhibitors
Immune checkpoint inhibitors, represented by anti-PD-1 antibodies, anti-PD-L1 antibodies and anti-CTLA-4 antibodies, have brought significant therapeutic benefits to many patients with advanced-stage malignancies. By releasing inhibitory signals on T cells, these agents enhance antitumor immune resp...
-д хадгалсан:
| Үндсэн зохиолчид: | , |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | Inglês |
| Хэвлэсэн: |
Taylor & Francis Group
2026-07-01
|
| Цуврал: | Immunological Medicine |
| Нөхцлүүд: | |
| Онлайн хандалт: | https://www.tandfonline.com/doi/10.1080/25785826.2026.2699471 |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|